1![November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent](https://www.pdfsearch.io/img/e1a15f00e57b6bfceef9aa072fc81cbf.jpg) | Add to Reading ListSource URL: dti.nm.orgLanguage: English - Date: 2014-11-12 14:34:06
|
---|
2![Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse](https://www.pdfsearch.io/img/36f2cf37dd8722eb778a123e295c6b14.jpg) | Add to Reading ListSource URL: www.campus-technologies.deLanguage: English - Date: 2014-11-10 10:17:25
|
---|
3![Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate](https://www.pdfsearch.io/img/3498579529b96094af93318279ba32eb.jpg) | Add to Reading ListSource URL: www.zft.uni-freiburg.deLanguage: English - Date: 2011-06-06 07:53:00
|
---|
4![A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments. (Photo: R. Baer) A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments. (Photo: R. Baer)](https://www.pdfsearch.io/img/1f71a85228f041601aa456bbf6c116c2.jpg) | Add to Reading ListSource URL: home.ccr.cancer.govLanguage: English - Date: 2010-07-09 15:00:30
|
---|
5![OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In](https://www.pdfsearch.io/img/bf3a891af5b89dc7c472596092e9b105.jpg) | Add to Reading ListSource URL: osp.od.nih.govLanguage: English - Date: 2013-12-31 12:39:20
|
---|
6![f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology](https://www.pdfsearch.io/img/e89af1278c7bdf07732329574db36681.jpg) | Add to Reading ListSource URL: home.ccr.cancer.govLanguage: English - Date: 2014-07-08 18:13:38
|
---|
7![VB6-845 Licensing Opportunity VIVENTIA Bio Inc. VB6-845 VB6-845 Licensing Opportunity VIVENTIA Bio Inc. VB6-845](https://www.pdfsearch.io/img/17e55af80da0017e76c00158a0ab2a93.jpg) | Add to Reading ListSource URL: www.viventia.comLanguage: English - Date: 2013-03-14 08:27:59
|
---|
8![f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology](https://www.pdfsearch.io/img/7c2c2ef4682866415b72e12f0925ee41.jpg) | Add to Reading ListSource URL: home.ccr.cancer.govLanguage: English - Date: 2014-06-26 13:56:08
|
---|
9![Fusogenics™: A novel approach to antibody affinity maturation Fusogenics™: A novel approach to antibody affinity maturation](https://www.pdfsearch.io/img/ec1b4c30599b494f7fba87889e7f3d5c.jpg) | Add to Reading ListSource URL: www.viventia.comLanguage: English - Date: 2013-03-14 08:27:25
|
---|
10![A preclinical profile of VB6-845: a recombinant immunotoxin for targeting ovarian cancer A preclinical profile of VB6-845: a recombinant immunotoxin for targeting ovarian cancer](https://www.pdfsearch.io/img/7c3d9ae46d4ee82a7398b4af9db41e4c.jpg) | Add to Reading ListSource URL: www.viventia.comLanguage: English - Date: 2013-03-14 08:26:09
|
---|